Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Prophylaxis of acute renal graft rejection Age: Adult |
Dose: Oral – 1 g Frequency: twice daily Note: Starting within 72 hours of transplantation. Maximum: 2 g/day. |
|
Indication: Prophylaxis of cardiac graft rejection Age: Adult |
Dose: Oral – 1.5 g Frequency: twice daily Note: Starting within 5 days after transplantation. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: less than 3 months |
Dose: Safety and efficacy not established Note: Safety and efficacy not established |
|
Indication: Prophylaxis of organ rejection in patients receiving allogeneic renal transplants Age: greater than 3 months |
Dose: Suspension – 600 mg/m² Frequency: every 12 hours Note: by mouth (oral); not to exceed 2 g/day |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Adult Condition: Severe renal impairment (glomerular filtration rate less than 25 mL/min/1.73 m2) |
Dose: MMF – 1 g Frequency: every 12 hours Note: Dosage not to exceed 1 g every 12 hours |
|
Condition: Renal transplant patients experiencing delayed graft function post-operatively |
Dose: MMF – Dosage adjustment not needed Note: No dosage adjustment needed in renal transplant patients experiencing delayed graft function post-operatively. |
Administration
- Take on empty stomach
- Space doses evenly
Side Effect
- Hyperglycemia (44%)
- Hypercholesterolemia (41%)
- Hypomagnesemia (39%)
- Dyspnea (37%)
- Back pain (35%)
- Increased blood urea nitrogen (BUN) (35%)
- Leukopenia (34%)
- Pleural effusion (34%)
- Urinary Tract Infection (UTI) (34%)
- Increasing frequency of cough (31%)
- Hypocalcemia (30%)
- Hypertension (28%)
- Abdominal pain (27%)
- Peripheral edema (27%)
- Anemia (26%)
- Fever (23%)
- Nausea (23%)
- Hyperkalemia (22%)
- Diarrhea (21%)
- Infection (21%)
- Headache (16%)
- Melanoma (1.6-4.2%)
- Other malignancies (0.7-2.1%)
- Lymphoma (0.4-1%)
- Opportunistic infection (including herpes)
- Neutropenia
- GI bleeding
- Pulmonary fibrosis
- Progressive multifocal leukoencephalopathy
- Angioedema
- anaphylaxis
- fatal pulmonary fibrosis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Aciclovir, valaciclovir, ganciclovir, valganciclovir
|
Increased plasma levels of both drugs
|
|
Colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer, other calcium-free phosphate binders
|
Reduced absorption
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
HGPRT deficiency
|
May cause severe reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in a cool (below 30°C), dry place and away from light. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.